# EDGAR Filing Document

**Accession Number:** 0001938046
**File Stem:** 0001493152-26-011914
**Filing Date:** 2026-3
**Character Count:** 9528
**Document Hash:** b9fa6a4a323e4c7e23a1183aa01d2991
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-26-011914.hdr.sgml**: 20260320

**ACCESSION NUMBER**: 0001493152-26-011914

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260316

**FILED AS OF DATE**: 20260320

**DATE AS OF CHANGE**: 20260320

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Cohen Jacob D.
- **CENTRAL INDEX KEY:** 0001432078

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41615
- **FILM NUMBER:** 26778991

**MAIL ADDRESS:**
- **STREET 1:** 2101 GLENDALE DRIVE
- **CITY:** PLANO
- **STATE:** TX
- **ZIP:** 75023
**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Tiger Cub Trust
- **CENTRAL INDEX KEY:** 0001974475

**ORGANIZATION NAME:**
- **STATE OF INCORPORATION:** TX
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41615
- **FILM NUMBER:** 26778990

**BUSINESS ADDRESS:**
- **STREET 1:** 19 RYDDINGTON PL
- **CITY:** DALLAS
- **STATE:** TX
- **ZIP:** 75230
- **BUSINESS PHONE:** 1 (214) 938-1217

**MAIL ADDRESS:**
- **STREET 1:** 19 RYDDINGTON PL
- **CITY:** DALLAS
- **STATE:** TX
- **ZIP:** 75230
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** MANGOCEUTICALS, INC.
- **CENTRAL INDEX KEY:** 0001938046
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 873841292
- **STATE OF INCORPORATION:** TX
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 15110 DALLAS PKWY, SUITE 600
- **CITY:** DALLAS
- **STATE:** TX
- **ZIP:** 75248
- **BUSINESS PHONE:** (833) 626-4679

**MAIL ADDRESS:**
- **STREET 1:** 15110 DALLAS PKWY, SUITE 600
- **CITY:** DALLAS
- **STATE:** TX
- **ZIP:** 75248

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Cohen Jacob D.<br><sub>(Last) (First) (Middle)</sub><br>C/O MANGOCEUTICALS, INC.<br>17130 N. DALLAS PARKWAY, SUITE 240<br><sub>(Street)</sub><br>DALLAS, TX 75248<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-03-16 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [X] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_Chief Executive Officer_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>MANGOCEUTICALS, INC. [ MGRX ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Tiger Cub Trust<br><sub>(Last) (First) (Middle)</sub><br>C/O MANGOCEUTICALS, INC.<br>17130 N. DALLAS PARKWAY, SUITE 240<br><sub>(Street)</sub><br>DALLAS, TX 75248<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-03-16 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [X] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>MANGOCEUTICALS, INC. [ MGRX ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock |  |  |  |  |  |  |  | 200000 | D<sup>(1)</sup> |  |
| Common Stock |  |  |  |  |  |  |  | 605000 | D<sup>(2)</sup> |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Stock Option (right to buy) | $16.50 | 2026-03-16 |  | D<sup>(3)</sup> |  |  | 50000 | <sup>(4)</sup> | 2027-09-01 | Common Stock | 50000 | $0 | 0 | D<sup>(1)</sup> |  |
| Stock Option (right to buy) | $0.45 | 2026-03-16 |  | A<sup>(3)</sup> |  | 50000 |  | <sup>(4)</sup> | 2027-09-01 | Common Stock | 50000 | $0 | 50000 | D<sup>(1)</sup> |  |
| Stock Option (right to buy) | $4.80 | 2026-03-16 |  | D<sup>(3)</sup> |  |  | 83333 | 2023-12-28 | 2028-12-28 | Common Stock | 83333 | $0 | 0 | D<sup>(1)</sup> |  |
| Stock Option (right to buy) | $0.45 | 2026-03-16 |  | A<sup>(3)</sup> |  | 83333 |  | 2023-12-28 | 2028-12-28 | Common Stock | 83333 | $0 | 83333 | D<sup>(1)</sup> |  |
| Stock Option (right to buy) | $2.30 | 2026-03-16 |  | D<sup>(3)</sup> |  |  | 2000000 | <sup>(5)</sup> | 2035-09-09 | Common Stock | 2000000 | $0 | 0 | D<sup>(1)</sup> |  |
| Stock Option (right to buy) | $0.45 | 2026-03-16 |  | A<sup>(3)</sup> |  | 2000000 |  | <sup>(5)</sup> | 2035-09-09 | Common Stock | 2000000 | $0 | 2000000 | D<sup>(1)</sup> |  |

---

### Footnotes:

(1) Represents Mr. Cohen's direct ownership of the Issuer.

(2) Shares held directly by The Tiger Cub Trust, which is beneficially owned by Jacob D. Cohen, its Trustee. Mr. Cohen disclaims beneficial ownership of the securities held by The Tiger Cub Trust except to the extent of his pecuniary interest therein.

(3) On March 16, 2026, the Issuer's Board of Directors, with the recommendation and approval of the Compensation Committee of the Board of Directors, approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced on March 16, 2026 (the "Effective Date") with a new exercise price of $0.45, which exceeded the closing price on Nasdaq as of the Effective Date. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

(4) A total of 1/3 of such options vested on each of September 1, 2023, 2024 and 2025.

(5) The options vest over 18 months with 500,000 of the options vesting upon grant on September 9, 2025, and 500,000 of the options vesting on the 6th, 12th, and 18th month anniversaries of the grant date, subject to Mr. Cohen's continued service with the Company on such vesting date; and vest in full upon any termination of Mr. Cohen by the Company without cause, or by Mr. Cohen for good reason, or upon a change of control of the Company.

**Signature:** /s/ Jacob D. Cohen  
**Date:** 2026-03-20

**Signature:** /s/ Jacob D. Cohen, Trustee, The Tiger Cub Trust  
**Date:** 2026-03-20

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**